Immunopharmacology

Preface
pp. vii-viii(2)
Authors: Parker C.J.; Janatova J.; Weis J.H.

Introduction
pp. ix-x(2)
Author: Hugli T.E.

Abstract contents list
pp. xi-xxvii(17)

Editorial board
pp. FM1-FM1(1)

Cloning and characterization of ascidian integrin subunits that function as a complement receptor type 3
pp. 3-3(1)
Authors: Miyazawa S.; Nonaka M.

Cytolytic complement system in invertebrates suggested by EST analysis of amphioxus notochord
pp. 3-3(1)
Authors: Suzuki M.; Satoh N.; Nonaka M.

An essential role of MASP-1 in activation of the lectin pathway
pp. 3-3(1)
Authors: Takahashi M.; Miura S.; Ishii N.; Matsushita M.; Endo Y.; Sugamura K.; Fujital T.

Mannan binding lectin binds complement receptor type 1 and augments IgG-stimulated phagocytosis
pp. 3-3(1)
Authors: Ghiran I.; Klickstein L.B.; Nicholson-Weller A.

High affinity C5 convertases of the alternative pathway of complement
pp. 4-4(1)
Authors: Rawal N.; Pangburn M.K.

C5a-stimulated human neutrophils utilize CR3,but not LFA-1 to supports the adhesion -dependent phase of superoxide production
pp. 4-4(1)
Authors: Tyagi S.; Klickstein L.B.; Nicholson-Weller A.

Expression of functional anaphylatoxin C5a receptors on hepatocytes after in-vivo treatment of rats with IL-6 as demonstrated by direct C5a-dependent glucose output
pp. 4-4(1)
Authors: Schieferdecker H.L.; Koleva M.; Schlaf G.; Gotze O.; Jungermann K.

Amyloid plaques in a transgenic mouse model of Alzheimer's disease (AD) contain complement components and pro-inflammatory cytokines
pp. 7-7(1)
Authors: Yu J.X.; Bradt B.M.; Hsiao K.; Cooper N.R.

Role of the phagocytic C1qR (C1qRp) in the CNS: Identification of the signalling events following C1pRp crosslinking
pp. 7-7(1)
Authors: McGreal E.P.; Dean Y.D.; van den Berg C.; Paul Morgan B.; Gasque P.

The membrane attack complex (MAC) of complement causes severe demyelination in vivo. Evidence from C6 deficient rats
pp. 7-7(1)
Authors: Mead R.J.; Singhrao S.; Neal J.W.; Paul Morgan B.

CRP mediates complement actiavation in human myocardial infarction
pp. 7-7(1)
Authors: Hack C.E.; Nijmeijer R.; Niessen H.W.M.; Visser C.A.; Lagrand T.K.

Engineering donor organs by perfusion with membrane-targeted biopharmaceuticals: In situ blockade of reperfusion-associated complement activation in experimental renal transplantation
pp. 8-8(1)
Authors: Pratt J.R.; Dong J.; Sacks S.H.; Smith R.A.G.

Crry-IG, an inhibitor of C3 activation, blocks anti-phospholipid AB (aPL) induced fetal loss
pp. 8-8(1)
Authors: Holers V.M.; Mo L.; Guthridge J.M.; Molina H.; Salmon J.E.

A role of complement component C5 in liver regeneration
pp. 8-8(1)
Authors: Mastellos D.; Papadimitriou J.C.; Franchini S.; Tsonis P.A.; Lambris J.D.

A new transcription factor involved in the transcriptional regulation of early complement components
pp. 11-11(1)
Author: Sullivan K.E.

P35-related gene expression in neutrophils as well as monocytes
pp. 11-11(1)
Authors: Kuraya M.; Endo Y.; Matsushita M.; Fujita T.

Molecular cloning of CIR/CIS-like serine protease from the common carp
pp. 11-11(1)
Authors: Nakao M.; Osaka K.; Kato Y.; Yano T.

Characterization of the human CR1-like transcript
pp. 11-11(1)
Authors: Birmingham D.J.; Logar C.M.; Chen W.

Two divergent C4 isotypes of the common carp
pp. 12-12(1)
Authors: Nakao M.; Mutsuro J.; Tanaka N.; Satoru-Totsuka; Kato Y.; Fujiki K.; Yano T.

C4-A like and C4-B like animal models
pp. 12-12(1)
Authors: Gadjeva M.; Carroll M.

Initial characterization of the Cobra Venom Factor gene
pp. 12-12(1)
Authors: Bammert H.; Kunze B.; Fritzinger D.C.; Bredehorst R.; Andra J.; Vogel C.-W.

Selection of a neoepitope specific anti gp C3adesArg single chain Fv fragment from a combinatoral rabbit antibody library
pp. 12-12(1)
Authors: Dahlke M.; Hawlisch H.; Link C.; Bautsch W.; Klos A.; Kohl J.

Cloning and purification of the rainbow trout fifth component of complement (C5)
pp. 13-13(1)
Authors: Franchini S.; Zarkadis I.K.; Sfyroera G.; Sahu A.; Lambris J.D.

Characterization of factor H-like molecules in rainbow trout
pp. 13-13(1)
Authors: Zarkadis I.K.; Sfyroera G.; Franchini S.; Sahu A.; Lambris J.D.

Genomic organisation of the human complement regulatory component factor H
pp. 13-13(1)
Authors: Schwaeble W.J.; Stover C.M.; Hanson S.; Weiss E.H.; Sim R.B.

Mutations of factor H (HF) in familial Hemolytic Uremic Syndrome (HUS) / Thrombotic Thrombocytopenic Purpura (TTP)
pp. 13-13(1)
Authors: Caprioli J.; Bettinaglio P.; Zipfel P.F.; Vasile B.; Gamba S.; Amadei B.; Orisio S.; Remuzzi G.; Noris M.

Factor I deficiency: Evaluation in three generations of a brazilian family
pp. 14-14(1)
Authors: Leitao M.F.; Condino-Neto A.; Grumach A.S.; Kirschfink M.

Molecular cloning of the cDNA of the C6A form of the sixth component of murine complement: Functional integrity despite the absence of factor I modules (FIMS)
pp. 14-14(1)
Authors: Yu J.X.; Bradt B.M.; Cooper N.R.

Human C6 deficiency has a homogeneous genetic background
pp. 14-14(1)
Authors: Fremeaux-Bacchi V.; Durey M.A.; Blouin J.; Kazatchkine M.D.

Characterization of the CR2/CD21 proximal promoter: Functional role for AP1/AP2 sites and two adjacent Ebox motifs
pp. 14-14(1)
Authors: Ulgiati D.; Virasch N.; Holers V.M.

Characterization of the mouse carboxypeptidase N small active subunit gene structure
pp. 15-15(1)
Authors: Matthews K.W.; Kildsgaard J.; Haviland D.L.; Wetsel R.A.

Characterization of the promoter of human procathepsin-L gene, a proteinase which cleaves human C3, the third component of complement and confers high tumorigenic and metastatic properties to human melanoma cells
pp. 15-15(1)
Authors: Jean D.; Guillaume N.; Frade R.

C1q enhances antibody-mediated uptake of the amyloid -peptide by microglia
pp. 15-15(1)
Authors: Webster S.D.; Galvan M.D.; Tenner A.J.

Complement C1q is dramatically upregulated in brain microglia in response to transient global cerebral ischemia
pp. 15-15(1)
Authors: Schwaeble W.J.; Schafer M.K.-H.; Post C.; Salvati P.; Calabresi M.; Sim R.B.; Petry F.; Loos M.; Weihe E.

C1 activation by amyloid fibrils. Evidence for a binding site for A on the C1q globular regions
pp. 16-16(1)
Authors: Tacnet P.; Galvan M.; Chevallier S.; Glabe C.; Tenner A.J.; Arlaud G.J.

Sublytic terminal complement complexes (TCC) rescued Schwann cells (SchC) from apoptosis via PI-3 kinase-Akt/PKB pathway
pp. 16-16(1)
Authors: Hila S.; Niculescu F.; Koski C.L.

Sublytic C5b-9 promotes OLG survival through inhibition of mitochondrial pathway of apoptosis
pp. 16-16(1)
Authors: Soane L.; Cho H.; Niculescu F.; Rus H.; Shin M.L.

Sublytic terminal complement complexes stimulate cell cycle activation in Schwann cells
pp. 16-16(1)
Authors: Hafer-Macko C.; Dashiell S.M.; Shin M.; Koski C.L.

Leukocyte migration in the cerebrospinal fluid induced by the injection of the terminal complement complex in the lateral ventricle of rats
pp. 17-17(1)
Authors: Casarsa C.; Pausa M.; De Luigi A.; De Simoni M.G.; Tedesco F.

Functional topology of the catalytic region of human C1s: Insights into the molecular determinants of C1s specificity
pp. 17-17(1)
Authors: Rossi V.; Bally I.; Thielens N.; Arlaud G.J.

Expression and binding properties of the homotrimeric forms of the globular regions of the A-, B- and C-chains of C1Q
pp. 17-17(1)
Authors: Reid K.B.M.; Strong P.; Perdikoulis M.V.; Kishore U.

Localization of C1qRp in human tissue
pp. 17-17(1)
Authors: Fonseca M.I.; Carpenter P.; Palmarini G.; Tenner A.J.

C1q deficiency and autoimmunity: The effects of genetic background on disease expression
pp. 18-18(1)
Authors: Mitchell D.; Cook H.; Botto M.; Walport M.

UVB-induced keratinocyte apoptosis in C1q deficient mice
pp. 18-18(1)
Authors: Pickering M.; Fischer S.; Cooke H.; Walport M.; Botto M.

Both IgG and IgM anti-pig antibodies induce complement activation and cytotoxicity
pp. 18-18(1)
Authors: Roos A.; Essers M.; van Gijlswijk-Janssen D.J.; Bovin N.V.; Daha M.R.

Opsonized immune complexes stimulate the production of TNF from macrophages
pp. 18-18(1)
Authors: Piliero L.; Sullivan K.

Cytokine regulation of complement secretion by HEPG2 cells
pp. 19-19(1)
Authors: Andrews E.; Lassiter H.; Feldhoff R.; Feldhoff P.

A role for complement in antibody-mediated inflammation: C5 deficient DBA/1 mice are resistant to collagen-induced arthritis
pp. 19-19(1)
Authors: Wang Y.; Kristan J.; Hao L.; Lenkoski C.S.; Shen Y.; Matis L.A.

Mechanisms of anti-C5 mediated protection following gastrointestinal ischemia-reperfusion: Analysis of intracellular adhesion molecule-1 (ICAM-1), tumor necrosis factor-(TNF), interleukin (IL) -1 and nitric oxide synthase (NOS)
pp. 19-19(1)
Authors: Montalto M.C.; Wada K.; Whoolery K.L.; Stahl G.L.

C-susceptibility of erythrocytes induced by spider and bacterial phospholipases is due to loss of membrane assymetry
pp. 19-19(1)
Authors: Tambourgi D.V.; da Sousa M.; Billington S.J.; Songer J.G.; van den Berg C.W.

The role of the complement system in the pathogenesis of atherosclerosis in mice
pp. 20-20(1)
Authors: Perrson L.; Nilsson A.-K.; Hietala A.; Pekna M.

Direct complement lysis as a major effector mechanism in rituximab (anti-CD20) therapy of B cell lymphomas
pp. 20-20(1)
Authors: Harjunpaa A.; Wiklund T.; Junnikkala S.; Janes R.; Collan J.; Rosenberg J.; Lee D.; Grillo-Lopez A.; Meri S.

The sibling family of sialoproteins bridge factor H to cell surfaces and protect cancer cell lines from lysis by ACP
pp. 20-20(1)
Authors: Fisher L.W.; Fedarko N.S.

Cytokines augment complement resistance of human breast carcinoma cells
pp. 20-20(1)
Authors: Garcia-Schuller H.; Jurianz K.; Ziegler S.; Rutz R.; Kirschfink M.

Bispecific antibody against CD55 and an antigen on cervical carcinoma cells induces C3b deposition and lysis
pp. 21-21(1)
Authors: Gelderman K.A.; Blok V.T.; Fleuren G.J.; Gorter A.

Cell cycle analysis of CD59 expression in ovarian cancer cell lines
pp. 21-21(1)
Authors: Bjorge L.; Matre R.; Meri S.

Cross-sectional study on soluble terminal-complement-pathway inhibitor levels in the Dutch population
pp. 21-21(1)
Authors: Harmsen T.; Kuipers S.; Mascini E.M.; van Dijk H.

Liver ischemia/reperfusion injury: A comparison of the protective effect of the complement inhibitors rsCR1 and C1 inhibitor
pp. 21-21(1)
Authors: Lehmann T.G.; Munch S.; Heger M.; Klar E.; Kirschfink M.

Crry-Ig, a complement activation inhibitor, protects mice from ischemia /reperfusion (IR) induced intestinal injury
pp. 22-22(1)
Authors: Fleming S.D.; Rehrig S.T.; Guthridge J.; Holers V.M.; Shea-Donohue T.; Tsokos G.C.

Phostacyclin analog epoprostenol and cobra venom factor prevents reperfusion injury and hyper acute rejection in discordant liver transplantation
pp. 22-22(1)
Authors: Meyer zu Vilsendorf A.; Link C.; Jorns A.; Kohl J.

Cobra Venom Factor (CVF) reduces hypoxicischemic (HI) cerebral edema in neonatal rats
pp. 22-22(1)
Authors: Lassiter H.; Feldhoff P.; Dabhia N.; Parker J.; Feldhoff R.

Role of complement activation in circulatory collapse: Studies with cobra venom factor hemorrhagic shock
pp. 22-22(1)
Authors: Younger J.; Sasaki N.; Till G.; Ward P.

C1-inhibitor potentiates the protective effect of graft preservation solution during cold storage
pp. 23-23(1)
Authors: Bergamaschini L.; Gobbo G.; Rossi E.; Ponti A.; Gatti S.; Caccamo L.; Braidotti P.; Agostoni A.

Abrogation of acute transplant rejection in the absence of locally synthesised C3
pp. 23-23(1)
Authors: Pratt J.R.; Basheer S.; Sacks S.H.

The complement system activity in nonspecific ulcerative colitis and after wobenzyme treatment
pp. 23-23(1)
Authors: Galebskaya L.V.; Niemerovsky V.S.; Ryumina E.V.; Aleshin Y.N.

Harmful effects of C5A in experimental sepsis
pp. 23-23(1)
Authors: Ward P.A.; Huber-Lang M.

Plasma soluble CR1 as a prognostic factor in severe burns
pp. 24-24(1)
Authors: Amodeo G.; D'Amelio L.; Palombo G.; D'Arpa N.; Accardo P.; Masellis M.; Brai M.

Deficiency of Decay-Accelerating Factor (DAF) attenuates leukocyte-endothelium interaction induced by hemorrhage and reinfusion
pp. 24-24(1)
Authors: Song W.; Scalia R.; Miwa T.; Lambris J.; Lefer A.

Opsonised immune complexes containing autoantigen and natural autoantibodies rescue peripheral blood B cells from apoptosis
pp. 24-24(1)
Authors: Leslie R.G.Q.; Kaveri S.; Kazatchkine M.D.; Fischer E.M.; Nielsen C.H.

Anti-complement treatment protects hypoxic reoxygenated huvecs from apoptosis
pp. 24-24(1)
Authors: Jordan J.E.; Morrissey M.; Stahl G.L.

Activation of complement by apoptotic endothelial cells following hypoxia/reoxygenation
pp. 25-25(1)
Authors: Mold C.; Morris C.A.

Tissue expression pattern of the mouse GPI-DAF and its potential role in a murine model of autoimmune disease
pp. 25-25(1)
Authors: Miwa T.; Maldonado M.; Sun X.; Ohta R.; Okada H.; Harris C.; Morgan B.; Eisenberg R.; Song W.

Molecular basis of a selective and complete C1S deficiency associated with multiple autoimmune diseases of early onset
pp. 25-25(1)
Authors: Dragon-Durey M.A.; Quartier P.; Fremeaux-Bacchi V.; Blouin J.; de Barace C.; Prieur A.; Weiss L.; Fridman W.H.

A C3a-receptor defective guinea pig strain exhibits decreased bronchial reactivity in an ovalbumin-induced asthma model
pp. 25-25(1)
Authors: Grove M.; Hoymann H.G.; Meyer-Wiedenbach I.; Zhang Q.; Raschke U.; Flemme N.; Meyer zu Vilsendorf A.M.; Klos A.; Kohl J.; Bautsch W.

Complement activation by the occupational allergen trimellitic anhydride (TMA)
pp. 26-26(1)
Authors: Regal J.F.; Larsen C.P.; Kane T.M.

Evaluating a role of complement activation in allergic lung damage induced by repeated inhalation of antigen
pp. 26-26(1)
Authors: Abe M.; Shimizu N.; Shibata K.; Sakata N.; Katsuragi T.; Akatsu H.; Okada H.

Comparative expression of anaphylatoxin C3a and C5a receptors on lung bronchial epithelial and smooth muscle cells in mouse models of asthma and sepsis
pp. 26-26(1)
Authors: Drouin S.M.; Kildsgaard J.; Haviland J.; Hong Pen Jia; McCray P.B.; Tack B.F.; Wetsel R.A.

Should we use probiotics as supportive treatment for hereditary angioedema?
pp. 26-26(1)
Authors: Madalinski K.; Jaworska H.; Gregorek H.

Analysis of immunoglobulins, complement and phagocyte in children anb adolescents with diabetes mellitus type 1
pp. 27-27(1)
Authors: Liberatore R.; Barbosa S.; Alkimin M.; Bellinati-Pires R.; Florido M.; Isaac L.; Kirschfink M.; Grumach A.

Hereditary C1 inhibitor deficiency increases the risk for renal diseases
pp. 27-27(1)
Authors: Carugati A.; Zingale L.C.; Rivolta E.; Agostoni A.; Cicardi M.

Autoimmune acquired C1-INH deficiency and anti-cardiolipin antibodies
pp. 27-27(1)
Authors: Gioffre D.; Barilla-La Barca M.; Zanichelli A.; Agostoni A.; Atkinson J.; Cicardi M.

Delayed resolution of inflammation in heterologous nephrotoxic nephritis in C1q deficient mice
pp. 27-27(1)
Authors: Robson M.G.; Cook H.T.; Botto M.; Walport M.J.; Davies K.A.

Accelerated nephrotoxic nephritis: Increased severity of disease in C1q deficient mice
pp. 28-28(1)
Authors: Robson M.G.; Cook H.T.; Taylor P.; Botto M.; Walport M.J.; Davies K.A.

Expression of plasma soluble CR1 and leukocyte surface CR1 in patients with glomerulonephritis
pp. 28-28(1)
Authors: Sivasankar B.; Ayub S.; Tiwari S.C.; Srivastava L.M.; Das N.

Expression of complement regulatory proteins in idiopathic focal segmental glomerulosclerosis
pp. 28-28(1)
Authors: Arora M.; Arora R.; Das N.; Srivastava L.M.

Complement factor C3 is not required for full expression of lupus nephritis in MRL/lpr mice
pp. 28-28(1)
Authors: Sekine H.; Colten H.; Garnier G.; Circolo A.; Gilkeson G.

Molecular basis of complete C4 deficiency in a SLE patient with four mutant genes: A 2- BP insertion at exon 29 in C4A and A 1-BP deletion at exon 13 in C4B
pp. 29-29(1)
Authors: Rupert K.L.; Moulds J.M.; Yang Y.; Warren R.; Reveille J.; Arnett F.C.; Yung Yu C.

Erythrocyte CR1 levels do not correlate with disease activity in hispanic SLE patients
pp. 29-29(1)
Authors: Moulds J.; Roberts S.; Tew M.; Reveille J.; Alarcon G.

Role of complement receptors type 1 (CR1/CD35) and type 2 (CR2/CD21) in murine SLE
pp. 29-29(1)
Authors: Boackle S.A.; Brown J.M.; Holers V.M.

CR1 polymorphisms associated with SLE
pp. 29-29(1)
Authors: Birmingham D.J.; Liang G.; Shen X.-P.

The 1-2-3 loci theory of human complement component C4: Heterozygosity in gene size and gene number as a mechanism to maintain C4 genetic diversity in the population
pp. 32-32(1)
Authors: Yung Yu C.; Blanchong C.A.; Zhou B.; Rupert K.L.; Yang Z.; Jones K.N.; Rennebohm R.M.

Chromatin accessibility and factor binding capability of the murine CD21 gene
pp. 32-32(1)
Authors: Zabel M.D.; Weis J.H.

Identification of the C3B binding site in the VWF-A domain of factor B by SELDI mass spectrometry and homology modelling
pp. 32-32(1)
Authors: Hinshelwood J.; Spencer D.I.R.; Edwards Y.J.K.; Perkins S.J.

X-ray crystal structure of the C4d fragment of human C4A
pp. 32-32(1)
Authors: van den Elsen J.M.H.; Martin A.; Wong V.B.; Rose D.R.; Isenman D.E.

Structure-guided identification of C3d residues essential for binding to complement receptor 2
pp. 33-33(1)
Authors: Clemenza L.; Isenman D.E.

X-ray structure of the human C1s catalytic domain: A protease with a CCP module handle
pp. 33-33(1)
Authors: Gaboriaud C.; Rossi V.; Bally I.; Arlaud G.; Fontecilla J.C.

Two molecular forms of MBL/MASP complexes differing in size, composition and biological activity are present in human plasma
pp. 33-33(1)
Authors: Jensenius J.C.; Matsushita M.; Thiel S.; Fujita T.

Targeted disruption of the murine phagocytic receptor ClqRp and phenotypic analysis
pp. 36-36(1)
Authors: Norsworthy P.J.; Fossati-Jimack L.; Taylor P.R.; Bygraves A.E.; Walport M.J.; Botto M.

Ultraviolet B (UVB) induces apoptosis and deposition of C3- and C4-derived ligands on primary human and murine keratinocytes in vivo: Implications for immune tolerance and the pathogenesis of SLE
pp. 36-36(1)
Authors: Zurowski N.; Navratil J.S.; Ursu S.; Nosce R.; Ahearn J.M.

Apoptotic endothelial cells and PBMC are tagged specifically by C3-and C4-derived ligands during membrane loss of RCA proteins: Implications for immune tolerance and the pathogenesis of SLE
pp. 36-36(1)
Authors: Navratil J.S.; Zurowski N.; Ahearn J.M.

A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo: A mechanism for protection against autoimmunity
pp. 36-36(1)
Authors: Botto M.; Taylor P.R.; Carugati A.; Fadok V.; Cook H.T.; Andrews M.; Carroll M.C.; Savill J.; Henson P.; Walport M.J.

Complement-ligand requirement for B lymphocyte survival in germinal centers during a primary response
pp. 37-37(1)
Authors: Barrington R.; Zhang M.; Pozdnyakova O.; Carroll M.

Role of CR2- and CD19-regulated natural antibodies in intestinal ischemia reperfusion-induced injury
pp. 37-37(1)
Authors: Fleming S.D.; Rehrig S.T.; Guthridge J.M.; Shea-Donohue T.; Tsokos G.C.; Holers V.M.

Role of complement and FC receptors in maintenance of B lymphocyte memory
pp. 37-37(1)
Authors: Barrington R.; Zafari M.; Fischer M.; Pozdnyakova O.; Benjamin C.; Carroll M.

Identification of the CH1 residue involved in the C3b covalent binding to human IgG
pp. 40-40(1)
Authors: Vidarte L.; Pastor C.; Mas S.; Guerrero R.; Blazquez A.B.; Vivanco F.

Localisation of ligand -binding sites on C1Q globular regions using single-chain antibodies
pp. 40-40(1)
Authors: Kojouharova M.S.; Tzacheva I.G.; Gadjeva M.G.; Tchorbadjieva M.I.; Kishore U.; Reid K.B.M.

C1Q mediates the clearance of apoptotic cells
pp. 40-40(1)
Authors: Ogden C.A.; Ghebrehiwet B.; Fadok V.; Henson P.

Glycosylation stabilizes cell surface expression of C1qRp
pp. 40-40(1)
Authors: Park M.; Tenner A.J.

Cloning and characterization of rat C1qRp
pp. 41-41(1)
Authors: Lovik G.; Vaage J.T.; Ryan J.C.; Szpirer C.; Dissen E.; Rolstad B.

Molecular cloning and tissue expression of the phagocytic complement C1q receptor in rat
pp. 41-41(1)
Authors: Dean Y.D.; McGreal E.P.; Akatsu H.; Paul Morgan B.; Gasque P.

A novel 3D model of C1-inhibitor based on the crystal structure of 4 intact serpins
pp. 41-41(1)
Authors: Bos I.G.A.C.; Hoedemaeker P.J.; Hack C.E.; Abrahams J.P.

Multiple mechanisms regulate C1 inhibitor (C1INH) induction by interferon- (IFN-)
pp. 41-41(1)
Authors: Zahedi K.; Prada A.; Mulligan A.; E. Davis A.

Investigation of C4bC2 complex formation by surface plasmon resonance
pp. 42-42(1)
Authors: Laich A.; Sim R.B.

Disruption of B cell tolerance in C4-l-anti-DNA transgenic mice
pp. 42-42(1)
Authors: Paul E.; Mandik-Nayak L.; Erikson J.; Carroll M.C.

Metal-dependent conformational changes in the vWF-A domain from factor B: A study by CD, FT-IR and ¹H NMR spectroscopy
pp. 42-42(1)
Authors: Hinshelwood J.; Perkins S.J.

Conformational changes during the assembly of factor B from its domains by ¹H NMR: The regulation of factor B activity
pp. 42-42(1)
Authors: Hinshelwood J.; J. Perkins S.

Extraordinary transcript of human factor B (Bf) generated by intron retention
pp. 43-43(1)
Authors: Jaatinen T.; Poutanen K.; Kanerva J.; Saarinen-Pihkala U.; Lokki M.-L.

Molecular cloning of complement factor B from a solitary ascidian: Unique combination of domains implicating ancient exon shufflings
pp. 43-43(1)
Authors: Ji X.; Namikawa-Yamada C.; Nakanishi M.; Sasaki M.; Nonaka M.

Synthesis of factor D by normal human hepatocytes
pp. 43-43(1)
Authors: Kitano E.; Kitamura H.

Proteomic analysis of C3 and its fragments
pp. 43-43(1)
Authors: Moore W.T.; Lambris J.D.

Control of complement expression: The role of cytokines in the regulation of C3 secretion in an H35 cell line
pp. 44-44(1)
Authors: Feldhoff P.; Stapp J.; Lassiter H.; Schrock M.; Feldhoff R.

The N-terminal part of the 2^nd extracellular loop of the C3aR B not involved in agonist binding
pp. 44-44(1)
Authors: Hawlisch H.; Bautsch W.; Klos A.; Kohl J.

Conjugation of complement C3d enhances the antibody response to pneumococcal serotype 14 capsular polysaccharide
pp. 44-44(1)
Authors: Test S.T.; Mitsuyoshi J.; Connolly C.C.; Lucas A.H.

Identification of the binding site on factor H SCR20 for C3D
pp. 44-44(1)
Authors: Sakari Jokiranta T.; Hellwage J.; Friese M.; Zipfel P.F.; Meri S.

Genomic organization and mutational characterization of human factor H: Implications in hemolytic uremic syndrome
pp. 45-45(1)
Authors: Sanchez-Corral P.; Perez-Caballero D.; Gallardo E.; Gonzalez-Rubio C.; Lopez-Trascasa M.; Rodriguez de Cordoba S.

Regulation of FHL-1/reconectin and Factor H transcription and RNA processing
pp. 45-45(1)
Authors: Friese M.A.; Hellwage J.; Eibel H.; Gordon D.L.; Sakari Jokiranta T.; Meri S.; Zipfel P.F.

Transcriptional regulation of factor H- related genes
pp. 45-45(1)
Authors: Ormsby R.; Male D.; Giannakis E.; Gordon D.

Sequence analysis of 222 KB of human genomic DNA containing the entire FH, FHR-1 and FHR-3 genes
pp. 45-45(1)
Authors: Male D.; Ormsby R.; Ranganathan S.; Giannakis E.; Gordon D.

Towards a 3D structure of functional site 2 of CR1-NMR studies of Complement Control Protein (CCP) modules 16 and 17
pp. 46-46(1)
Authors: Mallin R.; Smith B.O.; Uhrin D.; Krych-Goldberg M.; Wang X.; Atkinson J.P.; Barlow P.N.

Solution structure of complement control protein (CCP) modules 15 and 16 of CR1 - interpretation of mutagenesis experiments
pp. 46-46(1)
Authors: Smith B.O.; Uhrin D.; Krych-Goldberg M.; Wang X.; Atkinson J.P.; Barlow P.N.

CR2/CD21 SCR1,2 domain ligand binding, physical properties and structural analysis
pp. 46-46(1)
Authors: Guthridge J.; Rakstang J.; Young K.; Hinshelwood J.; Sarrias M.R.; Moore W.; Perkins S.J.; Overduin M.; Lambris J.D.; Karp D.; Hannan J.; Holers V.M.

Generation of novel C3dg tetramers for the analysis of CD21 binding and function
pp. 46-46(1)
Authors: Karp D.; Henson S.; Jones J.; Guthridge J.; Holers V.

Identification of a specific site within the human CR2/CD21 transcriptional silencer that controls lineage-specific repression: Interaction with a multi-protein complex containing CBF1, a target of the notch signaling pathway
pp. 47-47(1)
Authors: Holers V.M.; Ulgiati D.; Hagman J.; Makar K.W.

Expression of human complement receptor 2 (CR2, CD21)in CR2^-/- mice restores humoral immune function
pp. 47-47(1)
Authors: Marchbank K.J.; Watson C.C.; Ritsema D.F.; Holers V.M.

The complement receptor 3 (CR3) on Tlymphocytes: A regulatory molecule
pp. 47-47(1)
Authors: Wagner C.; Maria Hansch G.

C5a generation by alveolar macrophages
pp. 47-47(1)
Authors: Huber-Lang M.; Younkin E.; McGuire S.R.; Lu K.; Sarma V.; Ward P.A.

Expression and metabolic function of anaphylatoxin C5a receptors on Kupffer cells, stellate cells and sinusoidal endothelial cells but not on hepatocytes of normal rat liver
pp. 48-48(1)
Authors: Schlaf G.; Schieferdecker H.L.; Rothermel E.; Pestel S.; Jungermann K.; Gotze O.

Characterization of transgenic mice over expressing the complement anaphylatoxin C5a in the CNS
pp. 48-48(1)
Authors: Campos-Torres A.; Reiman R.; Martin B.; Campbell I.; Barnum S.

Antigen targeting by complement receptors
pp. 48-48(1)
Authors: Villiers C.L.; Perrin-Cocon L.A.; Chesne S.; Marche P.N.

Modulation of serum complement and macrophage activation by organophosphate insecticide malation
pp. 48-48(1)
Authors: Ayub S.; Sharma M.; Sivasankar B.; Katyal M.; Das N.

Natural autoantibodies and complement mediate B cell uptake of self antigens and their presentation to T cells
pp. 49-49(1)
Authors: Nielsen C.H.; Graham R.; Leslie Q.; Kaveri S.; Fischer E.; Kazatchkine M.D.

Tracing uptake of C3DG-conjugated antigen into B-cells via complement receptor type 2
pp. 49-49(1)
Authors: Hess M.; Schwendinger M.; Eskelinen E.; Pfaller K.; Pavelka M.; Dierich M.; Prodinger W.

Increased serum C3 in soluble Crry transgenic mice: Evidence of potential counter-regulation in the setting of chronic over-expression of a C3 convert ase inhibitor that partially abrogates its effects
pp. 49-49(1)
Authors: Kang H.J.; Bao L.; Ma Y.; Quigg R.; Giclas P.C.; Holers V.M.

Factor H on rodent platelets functions as the immune adherence receptor
pp. 49-49(1)
Authors: Alexander J.J.; Quigg R.J.

Regulated survival of activated B cells by complement receptors CD21/CD35
pp. 50-50(1)
Authors: Zhang M.; Barrington R.A.; Yang L.; Carroll M.C.

Follicular Dendritic Cells (FDC's) found in Bone Marrow (BM) are associated with B lymphocytes
pp. 50-50(1)
Authors: Pozdnyakova O.O.; Barrington R.A.; Carroll M.C.

Use of yeast two-hybrid screening to identify intracellular components which interact directly with the C3d/Epstein-Barr virus receptor (gp140, CR2, CD21) in human B lymphocytes
pp. 50-50(1)
Authors: le Romancer M.; Barel M.; Frade R.

Characterization of the P95 cellular component phosphorylated on tyrosine after activation of the C3d/Epstein-Barr virus receptor (gp140, CR2, CD21) on human B lymphocytes
pp. 50-50(1)
Authors: Barel M.; Frade R.

Identification and functional characterization of a new gene encoding the mouse terminal complement inhibitor CD59
pp. 53-53(1)
Authors: Qian Y.; Qin X.; Miwa T.; Sun X.; Halperin J.; Song W.

Derivatization of soluble human CD59 with a myristoylated peptide creates a potent membrane-bound inhibitor of complement-mediated lysis
pp. 53-53(1)
Authors: Smith G.P.; Dodd I.; Davies A.; Morgan B.P.; Lachmann P.J.; Smith R.A.G.

Kinetics and proposed mechanism of binding of the complement inhibitor compstatin
pp. 53-53(1)
Authors: Sahu A.; Soulika A.; Morikis D.; Spruce L.; Moore W.T.; Lambris J.D.

Pharmacology of SB 290157, a selective small molecule antagonist of the C3a receptor
pp. 53-53(1)
Authors: Ames R.S.; Lee D.; Foley J.J.; Tornetta M.A.; Bautsch W.; Settmacher B.; Klos A.; Sulpizio A.C.; Hieble J.P.; McCafferty G.; Sarau H.M.

Two clusters of acidic amino acids near the NH₂-terminus of C4 '-chain are important for C2 binding
pp. 54-54(1)
Authors: Pan Q.; Ebanks R.O.; Isenman D.E.

Membrane cofactor protein (MCP; CD46): Dissecting sites important for complement regulatory activity
pp. 54-54(1)
Authors: Liszewski M.K.; Leung M.; Cui W.; Bala Subramanian V.; Manchester M.; Parkinson J.; Barlow P.; Atkinson J.

Comparison of the factor H heparin binding sites on SCR domains 7 and 20
pp. 54-54(1)
Authors: Sakari Jokiranta T.; Hellwage J.; Male D.A.; Giannakis E.; Zipfel P.F.; Meri S.; Gordon D.L.

Structure and function of factor H: Mechanism of innate recognition of host and targets in the alternative pathway of complement
pp. 57-57(1)
Author: Pangburn M.K.

Onchocerca volvulus-microfilariae avoid complement attack by direct binding of factor H
pp. 57-57(1)
Authors: Meri T.; Sakari Jokiranta T.; Hellwage J.; Bialonski A.; Meri S.; Zipfel P.F.

A common site within factor H SCR 7 responsible for binding heparin, C-reactive protein and streptococcal M protein
pp. 57-57(1)
Authors: Giannakis E.; Male D.A.; Ormsby R.J.; Mold C.; Ranganathan S.; Gordon D.L.

Serum resistance of Borrelia burgdorferi correlates with binding of essential immune regulators of the factor H-protein family
pp. 57-57(1)
Authors: Kraiczy P.; Skerka C.; Kirschfink M.; Brade V.; Zipfel P.F.

Stable serum resistance of Neisseria gonorrhoeae is mediated by binding of C4B-binding protein to gonococcal porin
pp. 58-58(1)
Authors: Ram S.; Cullinane M.; Gulati S.; Blom A.; Dahlback B.; Elkins C.; Pangburn M.; McQuillen D.; Monks B.; Rice P.

A hemagglutinin-C3d2 fusion protein protects mice from lethal infection with influenza virus
pp. 58-58(1)
Authors: Liang H.; Ahearn J.M.

Herpes simplex virus evasion of complement attack
pp. 58-58(1)
Authors: Friedman H.; Saldanha C.; Wang L.; Jiang M.; Grippi K.; Lambris J.; Lubinski J.; Penn U.

C1 inhibitor (C11NH) target protease specificity
pp. 61-61(1)
Authors: Zahedi R.; Davis A.E.

Modulation of the alternative complement pathway by C1 inhibitor (C1 INH)
pp. 61-61(1)
Authors: Wagner E.; Jiang H.; Frank M.M.

C1-INH abuse: Whim or necessity
pp. 61-61(1)
Authors: Amodeo G.; Neri S.; Cicardi M.; Riela A.; Brai M.

C1-INH binds to endothelial cells and prevents cell metabolic failure after cold storage
pp. 61-61(1)
Authors: Gobbo G.; Bergamaschini L.; Macera F.; di Stefano R.; Agostoni A.

Increased C1-inhibitor levels and lack of contact system activation in plasma from patients with Crohn's disease
pp. 62-62(1)
Authors: Cugno M.; Vecchi M.; Devani M.; Sainz I.; de Franchis R.; Agostoni A.; Colman R.

Inhibition of endotoxin-induced oxidative burst by the C3 binding peptide compstatin in a novel whole blood model of inflammation
pp. 62-62(1)
Authors: Mollnes T.; Brekke O.; Kohl J.; Bergseth G.; Christiansen D.; Fure H.; Lappegard K.; Videm V.; Sahu A.; Lambris J.

Inhibition of heparin/protamine complex-induced complement activation by Compstatin in baboons
pp. 62-62(1)
Authors: Soulika A.M.; Khan M.M.; Hattori T.; Bowen F.W.; Richardson B.A.; Hack C.E.; Sahu A.; Edmunds L.H.; Lambris J.D.

Structural requirements for Decay Acclerating Activity (DAA) in complement receptor 1 (CR1; CD35)
pp. 62-62(1)
Authors: Krych-Goldberg M.; Hauhart R.; Blackmer D.; Atkinson J.P.

Expression of soluble and membrane-bound complement regulatory proteins by human hepatocytes
pp. 63-63(1)
Authors: Vogel H.; Halme J.; Kirschfink M.

TP10 (sCR1) increases protection against complement-mediated damage following xeno-transplantation of hDAF transgenic pig kidneys into cynomolgus monkeys
pp. 63-63(1)
Authors: Harrison R.; Vial C.; Soin B.; Masroor S.; Chavez G.; Bradley J.; Smith K.; Thiru S.; White D.; Friend P.; Cozzi E.

Soluble complement receptor (sCR1) 1 rescues rats from lethal shock induced by priming of sublethal dose of lipopolysaccharide (LPS) and anti-Crry antibodies
pp. 63-63(1)
Authors: Mizuno M.; Nishikawa K.; Okada N.; Okada H.; Matsuo S.

Development of a membrane-targeted complement inhibitor for clinical use
pp. 63-63(1)
Authors: Dodd I.; Oldroyd R.G.; Powell S.; Affleck L.J.; Bamber L.; Gallagher S.; Rowling P.J.E.; Ragnauth C.; Smith G.P.; Pratt J.R.; Sacks S.H.; Linton S.M.; Morgan B.P.; Smith R.A.G.

Characterization of the active site in Decay-Accelerating Factor (DAF)
pp. 64-64(1)
Authors: Kuttner-Kondo L.; Mitchell L.; Hourcade D.; Medof M.E.

Identification of a factor B site involved in the dissociation of the AP C3 convertase by decay accelerating factor
pp. 64-64(1)
Authors: Mitchell L.; Kuttner-Kondo L.; Medof M.E.; Hourcade D.

Complement inhibitory activity of decay accelerating factor (DAF; CD55) is not species restricted
pp. 64-64(1)
Authors: Harris C.L.; Spiller O.B.; Morgan B.P.

A direct comparison of complement inhibitory capacities of the GPI- and transmembrane forms of mouse DAF to mouse Crry and human rsCR1
pp. 64-64(1)
Authors: Kraus D.; Guthridge J.M.; Marsh H.C.; Holers V.M.

Molecular analysis of two closely related mouse decay-accelerating factor (CD55, DAF) genes: Identification in both of sequences encoding glycosylphosphatidylinositol-anchored and transmembrane forms of DAF
pp. 65-65(1)
Authors: Miwa T.; Fukuoka Y.; Okada N.; Kondor N.; Li W.; Okada H.

Pigs express multiple forms of decay accelerating factor (CD55), all of which contain only three Short Consensus Repeats (SCR)
pp. 65-65(1)
Authors: Perez de la Lastra J.M.; Harris C.L.; Hinchliffe S.J.; Holt D.S.; Rushmere N.K.; Morgan B.P.

Cooperation between decay accelerating factor and membrane cofactor protein in protecting cells from autologous complement attack
pp. 65-65(1)
Authors: Brodbeck W.G.; Mold C.; Atkinson J.P.; Medof M.E.

Studies to determine the structural effect of the N-glycan on CCP module 2 of membrane cofactor protein
pp. 65-65(1)
Authors: Herbert A.P.; Barlow P.N.

Characterisation of a transgenic pig line expressing high levels of CD46
pp. 66-66(1)
Authors: Loveland B.; Milland J.; Thorley B.; Christiansen D.; Kyriakou P.; Lanteri M.; French A.; Williams L.; Baker L.; Brandon M.; Bellomo R.; Baldwin I.; Kahn D.; McKenzie I.

Identification of the streptococcal M-protein binding site on membrane cofactor protein (CD46)
pp. 66-66(1)
Authors: Giannakis E.; Male D.A.; Ormsby R.J.; Loveland B.E.; Gordon D.L.

Characterization of MCP (CD46) transgenic mice
pp. 66-66(1)
Authors: Kemper C.; Leung M.; Kathryn Liszewski M.; Atkinson J.P.

Characterization of human membrane cofactor protein (MCP, CD46) on spermatozoa
pp. 66-66(1)
Authors: Kemper C.; Riley R.C.; Leung M.; Atkinson J.P.

Echovirus-infected cells are resistant to complement mediated lysis despite direct binding of CD55 and downregulation of remaining complement regulators
pp. 67-67(1)
Authors: Spiller O.; Goodfellow I.; Powell R.; Evans D.; Morgan B.

Role of CD59 upregulation in endothelial cells protected from complement in a model of xenotransplantation
pp. 67-67(1)
Authors: Dalmasso A.P.; Benson B.A.; Abrahamsen M.S.

Knocking out mouse CD59 using a PCR derived gene targeting vector
pp. 67-67(1)
Authors: Holt D.S.; Botto M.; Bygrave A.E.; Rushmere N.K.; Walport M.J.; Paul Morgan B.

Natural inhibitors of complement amplification: Anti-C3 antibodies from IVIG stimulate inactivation of C3bn-containing complexes
pp. 67-67(1)
Authors: Lutz H.U.; Stammler P.; Jelezarova E.

A novel anti-human factor B monoclonal antibody inhibits factor D-mediated association and cleavage of factor
pp. 68-68(1)
Authors: Kang B.H.J.; Mitchell L.M.; Hourcade D.E.; Holers V.M.

Inhibition of complement, neutrophil and platelet activation by a potent anti-factor D antibody during extracorporeal circulation
pp. 68-68(1)
Authors: Fung M.; Loubser P.; Mueller M.; Sun C.; Sun W.; Pinkston K.; Peng C.; Vaughn W.; Fraser C.; Undar A.

Inhibition of alternative pathway function with anti-properdin MoAbs
pp. 68-68(1)
Authors: Gupta-Bansal R.; Parent J.B.; Convery M.; Brunden K.R.

Efficacy of an anti-properdin MoAb in two models of complement-mediated tissue in jury
pp. 68-68(1)
Authors: Parent J.B.; Benzing W.C.; Gupta-Bansal R.; Convery M.; Anderson R.; Brunden K.R.

Therapeutic intervention in acute and chronic disease with anti-C5 therapy
pp. 69-69(1)
Author: Rollins S.A.

Novel inhibitory monoclonal antibodies to human CR2/CD21 ligand binding domains
pp. 69-69(1)
Authors: Guthridge J.; Young K.; Gipson M.; Hinshelwood J.; Sarrias M.R.; Lambris J.D.; Perkins S.J.; Holers V.M.

An IGG FC fragment peptide blocks interaction of IGG with C1Q
pp. 69-69(1)
Authors: Jiang H.; Frank M.M.

Regulation of the alternative pathway on injured cells by factor H, FHL-1 and C-reactive protein
pp. 69-69(1)
Authors: Jarva H.; Hellwage J.; Meri S.

Factor H-related proteins interact with C-reactive protein
pp. 70-70(1)
Authors: Hellwage J.; Jarva H.; Zipfel P.F.; Meri S.

Inhibition of human complement activity by human fibronectin-containing fraction
pp. 70-70(1)
Authors: Okada M.; Hitsumoto Y.

Inhibition of human C4 step by mouse fibronectin
pp. 70-70(1)
Authors: Hitsumoto Y.; Matsuda T.; Okada M.

Hirudin is an ideal anticoagulant for complement studies in a whole blood inflammatory model
pp. 70-70(1)
Authors: Fure H.; Bergseth G.; Brekke O.; Mollnes T.

Complement inhibitors to prevent (hyper-)acute vascular rejection: In vitro and in vivo results with IGM-enriched IVIG, C1-INH, and 5'000 d dextran sulfate
pp. 71-71(1)
Authors: Rieben R.; Dzelalija K.; Mohacsi P.

Hypersensitivity to taxol and doxil: Experimental and clinical evidence for a causal role of complement activation
pp. 71-71(1)
Authors: Szebeni J.; Baranyi L.; Savay S.; Chanan-Khan A.A.; Klein P.; Koenig K.; Muggia F.M.; Barenholz Y.; Danino D.; Talmon Y.; Alving C.R.

Echovirus and coxsackie B viruses that bind human CD55 are unable to use porcine CD55 as a receptor
pp. 71-71(1)
Authors: Spiller O.; Goodfellow I.; Harris C.; Perez de la Lastra J.; Evans D.; Morgan B.

Anti-GM2-IgM antibody in fresh human serum induces cytolysis to HIV-1 infected cells
pp. 71-71(1)
Authors: Okada N.; Wu X.; Yuki Y.; Okada H.

Determination of the factor H in sera of HIV infected patients by anti-factor H monoclonal antibodies
pp. 72-72(1)
Authors: Zhakhov A.; Fontaine M.; Verevochkin S.; Trofimov A.; Gilbert D.; Ischenko A.

Detachment of HIV-1 from follicular dendritic cells by blocking the C3D-CR2 interaction
pp. 72-72(1)
Authors: Kacani L.; Prodinger W.; Sprinzl G.; Schwendinger M.; Stoiber H.; Steindl F.; Dierich M.

Local synthesis of C3 in lymphoid tissues is sufficient to restore humoral responses to peripheral herpes simplex virus (HSV-1) infection in C3-deficient mice
pp. 72-72(1)
Authors: Verschoor A.; Brockman M.; Knipe D.; Carroll M.

Phenotypic induction of sensitivity to complement in complement-resistant Escherichia coli
pp. 72-72(1)
Authors: Ocana-Morgner C.; Dankert J.R.

Molecular identification of the CR1-related blood group antigens implicated in malarial infection
pp. 73-73(1)
Authors: Moulds J.; Zimmerman P.; Birmingham D.; Doumbo O.; Kassambara L.; Sagara I.; Atkinson J.; Krych M.; Hourcade D.; Miller L.

Interaction between complement and the malaria parasite in the mosquito vector
pp. 73-73(1)
Authors: Margos G.; Butcher G.A.; Davies A.; Sinden R.E.; Lachmann P.J.

Complement-group B meningococcal interactions: A study using isogenic mutant strains
pp. 73-73(1)
Authors: Ram S.; Vogel U.; Gulati S.; Heinze G.; Van der Ley P.; Frosch M.; Rice P.A.

The molecular basis of group B meningococcal serum resistance
pp. 73-73(1)
Authors: Ram S.; Mackinnon F.; Gulati S.; Vogel U.; Gorringe A.; Rice P.

A cluster of positively charged amino acids at the interface between C4BP CCP1 and CCP2 is crucial for binding of C4b and streptococcal proteins
pp. 74-74(1)
Authors: Blom A.M.; Villoutreix B.O.; Webb J.H.; Berggard K.; Foltyn-Zadura A.; Lindahl G.; Dahlback B.

The membrane attack complex inhibitor of streptococcus pyogenes (SIC) binds preferentially to C567
pp. 74-74(1)
Authors: Fernie-King B.A.; Seilly D.J.; Davies A.; Lachmann P.J.

Effects on C3 of the secreted cathepsin L proteinases from the parasite Fasciola hepatica
pp. 74-74(1)
Authors: Ciganda M.; Willis A.C.; Dalton J.P.; Diaz A.

Vaccination responses to Neisseria meningitidis and Haemophilus influenzae type b in two C2-deficient sisters
pp. 74-74(1)
Authors: Selander B.; Kayhty H.; Wedege E.; Holmstrom E.; Truedsson L.; Soderstrom C.; Sjoholm A.G.

Characterization of an inhibitor of complement activation from the parasite Echinococcus granulosus
pp. 75-75(1)
Authors: Irigoin F.; Ferreira F.; Laich A.; Fernandez C.; Ferreira A.; Sim R.B.; Diaz A.

Bordetella pertussis binds to human C4BP (C4B-binding protein) at a site similar to that used by the natural ligand C4b
pp. 75-75(1)
Authors: Berggard K.; Lindahl G.; Dahlback B.; Blom A.

Studies on the borreliacidal activity of early lyme disease sera against complement-resistant borrelia afzelii FEM1 wild-type and an OspC-lacking FEM1 variant
pp. 75-75(1)
Authors: Kraiczy P.; Hunfeld K.-P.; Wurzner R.; Acker G.; Brade V.

Attachment of Neisseria gonorrhoeae to the cellular pilus receptor CD46: Identification of domains important for bacterial adherence
pp. 75-75(1)
Authors: Kallstrom H.; Blackmer D.J.; Kathryn Liszewski M.; Atkinson J.P.; Jonsson A.-B.

Heparin binding activity (due to putative K/R-X-R/K sites) of vaccinia virus complement control protein confers numerous functions with tremendous therapeutic potential and implications in viral evasion
pp. 76-76(1)
Authors: Kotwal G.J.; Smith S.; Al Mohanna F.; Parhar R.; Srisatjaluk R.; Justus D.E.; Mullins N.; Parkinson J.; Barlow P.

Ficolins activate the lectin complement pathway
pp. 79-79(1)
Authors: Matsushita M.; Endo Y.; Hamasaki N.; Fujita T.

Mannan-binding lectin associated serine protease 3 (MASP-3) - a new component of the lectin pathway of complement activation
pp. 79-79(1)
Authors: Dahl M.R.; Thiel S.; Willis A.C.; Vorup-Jensen T.; Christensen T.; Petersen S.V.; Jensenius J.C.

Reconstitution of the complement (C) function in C1Q deficient (CIQA-/-) mice with wild type bone marrow cells
pp. 79-79(1)
Authors: Petry F.; Botto M.; Walport M.; Loos M.

C4- and CD21/CD35-deficiency predisposes mice to spontaneous autoreactivity
pp. 79-79(1)
Authors: Pozdnyakova O.O.; Paul E.; Schneider T.J.; Carroll M.C.

Activation of the alternative complement pathway in factor D-deficient mice
pp. 80-80(1)
Authors: Xu Y.; Ma M.; Ippolito G.C.; Johnson R.S.; Szalai A.J.; Spiegelman B.M.; Schroeder H.W.; Carroll M.C.; Volanakis J.E.

Regulation of the alternative pathway of complement activation is critical for the maintenance of fetomaternal tolerance
pp. 80-80(1)
Authors: Molina H.; Xu C.; Mao D.

Contraposition of endotoxin-induced shock in C3A receptor- and C3-deficient mice
pp. 80-80(1)
Authors: Kildsgaard J.; Hollmann T.J.; Matthews K.W.; Drouin S.M.; Haviland D.L.; Wetsel R.A.

C3aR: A central mediator of allergic asthma
pp. 80-80(1)
Authors: Humbles A.; Lu B.; Gerard N.; Gerard C.

Control of the MBL pathway of complement activation
pp. 83-83(1)
Authors: Vang Petersen S.; Thiel S.; Vorup-Jensen T.; Jensen L.; Christian Jensenius J.

Interaction of mannan-binding lectin with IgA
pp. 83-83(1)
Authors: Roos A.; van Gijlswijk-Janssen D.J.; Faber-Krol R.; Daha M.R.

C4b-Binding protein and mannose binding lectin interactions with 2-glycoprotein I: Association of complement activation and antiphospholipid antibodies
pp. 83-83(1)
Authors: Sim D.S.; Thiel S.; Devine D.V.

Characterization of monoclonal antibodies (mAb) against native and recombinant human mannose-binding lectin (MBL)
pp. 83-83(1)
Authors: Zhao H.; Stahl G.L.

Analysis of mouse mannan-binding lectin A and C
pp. 84-84(1)
Authors: Liu H.; Jensen L.; Hansen S.; Vang Petersen S.; Takahashi K.; Ezekowitz A.; Hansen F.; Jensenius J.C.; Thiel S.

A ficolin-like lectin in the plasma of the solitary ascidian, Halocynthia roretzi
pp. 84-84(1)
Authors: Kenjo A.; Takahashi M.; Matsushita M.; Endo Y.; Fujita T.

Comparison of binding and functional effects of MBL and C1q on lymphocytes and macrophages
pp. 84-84(1)
Authors: Erdei A.; Bajtay Z.; Jozsi M.; Banki Z.; Thiel S.; Thielens N.

Construction and expression of variant forms of human mannose-binding lectin
pp. 84-84(1)
Authors: Larsen F.; Madsen H.O.; Koch C.; Garred P.

Plasma level of mannan-binding lectin (MBL) as predictor of sepsis after chemotherapy
pp. 85-85(1)
Authors: Thiel S.; Anker Peterslund N.; Koch C.; Jensenius J.C.

Mannan-binding protein (MBP)-dependent cell-mediated cytotoxicity (MDCC)
pp. 85-85(1)
Authors: Kawasaki T.; Ma Y.; Uemura K.; Kawasaki N.

Endothelial oxidative stress increases cytokeratin 1 (k1) expression and human mannose-binding lectin (MBL) deposition
pp. 85-85(1)
Authors: Collard C.D.; Montalto M.; Stahl G.L.

Inherited deficiency of mannose-binding lectin is predominantly a type II deficiency state
pp. 85-85(1)
Authors: Garred P.; Madsen H.O.; Larsen F.; Koch C.

Mannose binding lectin (MBL) contributes to complement activation in glomerulonephritis
pp. 86-86(1)
Authors: Endo M.; Ohsawa I.; Satomura A.; Hidaka M.; Fujita T.; Ohi H.; Matsushita M.; Fujita T.

Recombinant expression of human mannan binding lectin
pp. 86-86(1)
Authors: Vorup-Jensen T.; Sorensen E.S.; Jensen U.B.; Poulsen K.; Schwaeble W.; Kawasaki T.; Wakamiya N.; Jensen T.G.; Takahashi K.; Ezekowitz R.A.B.; Thiel S.; Jensenius J.C.

Organization of the human and murine MASP-2 gene cluster
pp. 86-86(1)
Authors: Stover C.M.; Schwaeble W.J.

The binding of mannan binding lectin parallels the expression of complement receptor 1 (CR1, CD35) on erythrocytes and neutrophils
pp. 86-86(1)
Authors: Ghiran I.; Barbashov S.; Klickstein L.; Nicholson-Weller A.

Expression and characterization of the MAp19 component of the MBL pathway of complement
pp. 87-87(1)
Authors: Thielens N.; Cseh S.; Thiel S.; Rossi V.; Jensenius J.; Arland G.

The evolution of human mannosebinding lectin genes mbl1 and mbl2
pp. 87-87(1)
Authors: Madsen H.O.; Svejgaard A.; Ryder L.P.; Garred P.

Mannose-binding lectin in the Netherlands: Prevalence of normal and aberrant levels in a healthy population
pp. 87-87(1)
Authors: Kuipers S.; Harmsen T.; Mascini E.; Takahashi K.; van Djik H.

Interaction of HIV-1 with mannose binding lectin
pp. 87-87(1)
Authors: Spear G.T.; Hart M.L.; Saifuddin M.; Zhang Y.; Xu B.; Gewurz H.

Regulation of the inflammatory response to Nelsseria meningitidis B1940 by mannose-binding lectin
pp. 88-88(1)
Authors: Jack D.; Vogel U.; Tenner A.; Frosch M.; Turner M.; Klein N.

Meningococcal lipopolysaccharide sialylation alters the bactericidal activity of human mannose-binding lectin
pp. 88-88(1)
Authors: Jack D.; Jarvis G.; Booth C.; Li J.; Klein N.; Turner M.

Study of MBL-MASPs interaction with C1-inhibitor and ₂-macroglobulin
pp. 88-88(1)
Authors: Kojima M.; Sim R.

Interactions between MBL and the MASP proteins in lectin pathway hemolysis
pp. 88-88(1)
Authors: Xu B.; Zhang Y.; Takahashi K.; Ezekowitz A.R.; Lint T.F.; Gewurz H.

Analysis of MASP-2 activation by mutagenesis studies
pp. 89-89(1)
Authors: Gadjeva M.; Vorup-Jensen T.; Hansen A.; Thiel S.; Jensenius J.C.

The cleavage of two C1s subunits by a single active C1r reveals substantial flexibility of the C1s-C1r-C1r-C1s tetramer in the C1 complex
pp. 89-89(1)
Authors: Zavodszky P.; Lorincz Z.; Cseh S.; Dobo J.; Szilagyi K.; Ambrus G.; Gal P.

Structure/function analysis of the C3a-receptor C-terminus
pp. 89-89(1)
Authors: Settmacher B.; Rheinheimer C.; Oppermann M.; Hamacher H.; Bock D.; Kohl J.; Bautsch W.; Klos A.

C5a- and C3a-receptors detected with high affinity monoclonals of rabbit and mouse origin
pp. 89-89(1)
Authors: Chronopoulou E.; Ember J.A.; Song S.; Pu Dong L.; Ji X.-D.; Dong Wang X.; Zou J.-C.; Shi L.; Stall A.; Sanderson S.D.; C-Y Shih C.; Morgan E.

Phosphorylation by a casein kinase from activated human platelets increases the binding of C3b to CR1
pp. 90-90(1)
Authors: Nilsson Ekdahl K.; Olsson L.; Nilsson B.

Effect of M-prednisolone upon the complement and Fc receptors ability of mediating oxidative burst of neutrophils
pp. 90-90(1)
Authors: Marzocchi-Machado C.; Russo E.; Alves C.; Azzolini A.; Polizello A.; Lucisano-Valim Y.

An in vitro, complement-dependent model of particle transfer from erythrocytes to macrophages
pp. 90-90(1)
Authors: Vincent J.A.; Lacouture M.E.; Nicholson-Weller A.; Klickstein L.B.

Macrophages and xenoreactive antibodies mediate delayed xenograft rejection in the discordant guinea pig to rat species combination
pp. 90-90(1)
Authors: Link C.; Kohl J.

Activation of porcine endothelial cells by human complement
pp. 91-91(1)
Authors: Fecke W.; Long J.; Richards A.; Harrison R.

New neo-epitope specific ELISA kits to determine anaphylatoxin C3a_desArg and C5a_desArg levels in biological fluids
pp. 91-91(1)
Authors: Ember J.A.; Windman S.; Jun Luan F.; Sasaki S.; Shi L.; Stall A.; C-Y Shih C.; Kolb W.P.; Morgan E.

Lysis of rabbit erythrocytes by human serum requires anti-GAL antibody, the alternative complement pathway, and C1Q
pp. 91-91(1)
Authors: Walpen A.; Mohacsi P.; Rieben R.

Distribution of decay accelerating factor (DAF/CD55) on pig cells and tissues
pp. 91-91(1)
Authors: Perez de la Lastra J.M.; Harris C.L.; Morgan B.P.

Pig-P, the fourth protein associated with Pig-A that is responsible for paroxysmal nocturnal hemoglobinuria
pp. 92-92(1)
Authors: Kinoshita T.; Watanabe R.; Murakami Y.; Inoue N.; Maeda Y.; Hino J.; Kangawa K.

Alternative exon usage in the 3'region of a single gene generates glycosylphosphatidylinositol-anchored and transmembrane forms of rat decay-accelerating factor
pp. 92-92(1)
Authors: Miwa T.; Okada N.; Okada H.

Tissue distribution of mouse CD59 analyzed using a novel rat anti-mouse CD59 monoclonal antibody
pp. 92-92(1)
Authors: Hanna S.M.; Harris C.L.; Morgan B.P.

Transfer of GPI-anchored CD59 requires cell to cell contact
pp. 92-92(1)
Authors: van den Berg C.W.; Capey S.

Effects of mutant PIG-A on gene expression
pp. 93-93(1)
Authors: Kim K.-C.; Vreeke T.M.; Parker C.J.

Activation of STAT3 by sublytic C5b-9 in human aortic endothelial cells induces cell cycle
pp. 93-93(1)
Authors: Niculescu F.; Soane L.; Badea T.; Shin M.L.; Rus H.

Molecular cloning and expression of human RGC-32, a novel gene induced by complement and involved in CDC2 activation
pp. 93-93(1)
Authors: Badea T.; Niculescu F.; Soane L.; Shin M.L.; Rus H.

Effect of complement mediators on eosinophil activation
pp. 93-93(1)
Authors: DiScipio R.G.; Sriramarao P.; Schraufstatter I.

In-vitro inhibition of histamine and thromboxane release from mast cells by high-dose intravenous immunoglobuli (IVIG)
pp. 94-94(1)
Author: Basta M.

Analysis of the structure/function relationship of Cobra Venom Factor (CVF) and C3: Generation of CVF/cobra-C3 hybrid proteins
pp. 94-94(1)
Authors: Wehrhahn D.; M. Meiling K.; Fritzinger D.C.; Bredehorst R.; Andra J.; Vogel C.-W.

Transgenic mice expressing cobra venom factor
pp. 94-94(1)
Authors: Andra J.; Halter R.; Heske C.; Paul D.; Vogel C.-W.

Complement-dependent and -independent activities of cobra venom factor-treated chicken serum
pp. 94-94(1)
Authors: Koppenheffer T.L.; Parker K.P.

Loxosceles spider venom induces cleavage of MCP/CD46 and increases C-resistance by activation of metalloproteinases
pp. 95-95(1)
Authors: van den Berg C.W.; de Andrade R.M.G.; Magnoli F.C.; Tambourgi D.V.

Induction of apoptosis by the terminal sequence of complement
pp. 95-95(1)
Authors: Nauta A.J.; Daha M.R.; Roos A.

C-mannosylation of tryptophan residues in properdin and the terminal complement proteins
pp. 95-95(1)
Authors: Hartmann S.; Hess D.; Blommers M.; Furmanek A.; Hofsteenge J.

Efficient assembly of a C3 convertase on C3B₂-IGG complexes
pp. 95-95(1)
Authors: Jelezarova E.; Lutz H.U.

Monitoring of complement activation on a biomaterial surface
pp. 96-96(1)
Authors: Andersson J.; Nilsson Ekdahl K.; Nilsson B.

Molecular characterization of the covalent complexes of C3b with the Fc region of human IgG
pp. 96-96(1)
Authors: Pastor C.; Vidarte L.; Mas S.; Guerrero R.; Blazquez A.B.; Vivanco F.

Localisation of the protein S binding site on the C4BP -chain
pp. 96-96(1)
Authors: Webb J.H.; Villoutreix B.O.; Dahlback B.; Blom A.M.

C5A-mediated release of IL-6 from C5A receptor-bearing human osteoblasts
pp. 96-96(1)
Authors: Sanderson S.; Reinhardt R.; Jackson J.

Significant expression of guinea pig C4B- binding protein -chain in epididymis by alternative promoter usage
pp. 97-97(1)
Authors: Nonaka M.; Wang G.; Okada H.; Nonaka M.

Complexes of factor H and phospholipids induce pathogenic antiphospholipid antibodies in a murine model
pp. 97-97(1)
Authors: Myones B.; Espinola R.; Liu X.; Antonov I.; Harris E.; Pierangeli S.

Identification of HSC70 and -tubulin in L-CIP, the large complement-induced protein complex
pp. 97-97(1)
Authors: Fishelson Z.; Hochman I.; Bohana-Kashtan O.

Species and pathway-specific activation of complement by a phosphorothioate oligonucleotide
pp. 97-97(1)
Authors: Henry S.; Jagels M.; Hugli T.; Giclas P.

Preface
pp. 99-100(2)
Authors: Parker C.J.; Janatova J.; Weis J.H.

Introduction
pp. 101-102(2)
Author: Hugli T.E.

Functional domains, structural variations and pathogen interactions of MCP, DAF and CR1
pp. 103-116(14)
Authors: Hourcade D.; Kathryn Liszewski M.; Krych-Goldberg M.; Atkinson J.P.

Functional domains, structural variations and pathogen interactions of MCP, DAF and CR1
pp. 103-116(14)
Authors: Hourcade D.; Liszewski M.K.; Krych-Goldberg M.; Atkinson J.P.

Immunomodulatory functions of murine CR1/2
pp. 117-124(8)
Authors: Prechl J.; Erdei A.

Immunomodulatory functions of murine CR1/2
pp. 117-124(8)
Authors: Prechl J.; Erdei A.

Phenotypes of complement knockouts
pp. 125-131(7)
Author: Holers V.M.

Phenotypes of complement knockouts
pp. 125-131(7)
Author: Holers V.M.

Complement inhibitors: a resurgent concept in anti-inflammatory therapeutics
pp. 133-148(16)
Authors: Sahu A.; Lambris J.D.

Complement inhibitors: a resurgent concept in anti-inflammatory therapeutics
pp. 133-148(16)
Authors: Sahu¹ A.; Lambris J.D.

Host recognition and target differentiation by factor H, a regulator of the alternative pathway of complement
pp. 149-157(9)
Author: Pangburn M.K.

Host recognition and target differentiation by factor H, a regulator of the alternative pathway of complement
pp. 149-157(9)
Author: Pangburn M.K.

C1q: Structure, function, and receptors
pp. 159-170(12)
Authors: Kishore U.; Reid K.B.M.

C1q: structure, function, and receptors
pp. 159-170(12)
Authors: Kishore U.; Reid K.B.M.

Complement components of the innate immune system in health and disease in the CNS
pp. 171-186(16)
Authors: Gasque P.; Dean Y.D.; McGreal E.P.; VanBeek J.; Morgan B.P.

Complement components of the innate immune system in health and disease in the CNS
pp. 171-186(16)
Authors: Gasque P.; Dean Y.D.; McGreal E.P.; VanBeek J.; Morgan B.P.

Complement and innate immunity
pp. 187-198(12)
Authors: Song W.-C.; Rosa Sarrias M.; Lambris J.D.

Complement and innate immunity
pp. 187-198(12)
Authors: Song¹ W.-C.; Sarrias M.R.; Lambris J.D.

Author index of abstracts
pp. 199-217(19)

Keyword index abstracts
pp. 219-223(5)

Author index of reviews
pp. 225-225(1)